Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Non Operating Income: 2023-2024

Historic Non Operating Income for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $8.6 million.

  • Contineum Therapeutics' Non Operating Income rose 42.15% to $2.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.6 million, marking a year-over-year increase of 21.77%. This contributed to the annual value of $8.6 million for FY2024, which is 21.75% up from last year.
  • Contineum Therapeutics' Non Operating Income amounted to $8.6 million in FY2024, which was up 21.75% from $7.1 million recorded in FY2023.
  • In the past 5 years, Contineum Therapeutics' Non Operating Income ranged from a high of $8.6 million in FY2024 and a low of $7.1 million during FY2023.
  • Its 2-year average for Non Operating Income is $7.9 million, with a median of $7.9 million in 2023.
  • Data for Contineum Therapeutics' Non Operating Income shows a peak YoY grew of 21.75% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Contineum Therapeutics' Non Operating Income stood at $7.1 million in 2023, then rose by 21.75% to $8.6 million in 2024.